We are live on ! Find out more
GENE

Genetic Technologies Ltd.
GENE

Delisted

GENE was delisted on the 16th of October, 2024.

Back to rankings

14 hedge funds and large institutions have $910K invested in Genetic Technologies Ltd. in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less funds holding

Funds holding: 16 → 14 (-2)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

27% less capital invested

Capital invested by funds: $1.25M → $910K (-$343K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$5.92K
2
UBS Group
UBS Group
Switzerland
+$2.2K
3
FANJ
Financial Architects (New Jersey)
New Jersey
+$946
4
Fifth Third Bancorp
Fifth Third Bancorp
Ohio
+$118

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$167K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$79.1K
3
VF
Virtu Financial
New York
-$39K
4
AGM
Alpine Global Management
New York
-$30K
5
Citadel Advisors
Citadel Advisors
Florida
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$833K -$167K -7,053 -14%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$27K -$79.1K -3,342 -71%
Cambridge Investment Research Advisors
3
Cambridge Investment Research Advisors
Iowa
$17K +$5.92K +250 +42%
Jane Street
4
Jane Street
New York
$13K -$875 -37 -5%
Parallax Volatility Advisers
5
Parallax Volatility Advisers
California
$5K – – –
UBS Group
6
UBS Group
Switzerland
$5K +$2.2K +93 +55%
CG
7
Cutler Group
California
$4K – – –
LTFS
8
Ladenburg Thalmann Financial Services
Florida
$3K – – –
Morgan Stanley
9
Morgan Stanley
New York
$2K – – –
FANJ
10
Financial Architects (New Jersey)
New Jersey
$1K +$946 +40 +222%
RE
11
RBC Europe
United Kingdom
$79 – – –
VF
12
Virtu Financial
New York
– -$39K -1,875 Closed
AGM
13
Alpine Global Management
New York
– -$30K -1,422 Closed
Citadel Advisors
14
Citadel Advisors
Florida
– -$19K -893 Closed
Simplex Trading
15
Simplex Trading
Illinois
– -$1.3K -55 -65%
Fifth Third Bancorp
16
Fifth Third Bancorp
Ohio
– +$118 +5 New

GENE Hedge Fund Activity: Q2 2018 in Review

14 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q2 2018, worth a combined $910K — down 27% from $1.25M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of GENE and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Cambridge Investment Research Advisors, adding an estimated $5.92K. The largest seller was Renaissance Technologies, cutting an estimated $167K.

  • 14 institutional investors held Genetic Technologies Ltd. (GENE) as of Q2 2018, down from 16 in Q1 2018.
  • Funds reported $910K of Genetic Technologies Ltd. stock for Q2 2018, down 27% quarter-over-quarter.
  • 1 fund opened new Genetic Technologies Ltd. positions in Q2 2018 and 3 closed out, a net change of -2 holders.
  • The largest Genetic Technologies Ltd. buyer in Q2 2018 was Cambridge Investment Research Advisors, an estimated $5.92K added.
  • The largest Genetic Technologies Ltd. seller in Q2 2018 was Renaissance Technologies, an estimated $167K sold.

Based on aggregated 13F filings for Q2 2018.